Phase I Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors

Trial Profile

Phase I Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Feb 2018

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 13 Feb 2018 According to the results published in the Journal of Clinical Oncology primary end point (ie, toxicity) of the study was amended from 6 months follow-up to 3 months.
    • 13 Feb 2018 Results published in the Journal of Clinical Oncology
    • 02 Jan 2018 Status changed from active, no longer recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top